How the protein ATP1B3 affects T cells in autoimmunity
ATP1B3: novel regulator of T cell-mediated immunity
This project looks at whether the protein ATP1B3 helps control T cell activity that drives autoimmune diseases and could point to new drug targets for people with autoimmune conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11170769 on NIH RePORTER |
What this research studies
If you have an autoimmune condition, this research is exploring a protein called ATP1B3 that may change how T cells behave. Researchers used genetic screens to find ion channel and transporter genes that influence T cell responses and are now focusing on components of the sodium-potassium pump. The work will involve lab studies of T cells and related experiments to see how altering ATP1B3 changes immune signals that can cause autoimmunity. Findings could guide future efforts to develop medicines that calm harmful T cell activity.
Who could benefit from this research
Good fit: People with autoimmune diseases who are interested in contributing blood or tissue samples or who might join future clinical trials focused on T cell-targeting therapies would be most relevant.
Not a fit: People without autoimmune conditions or whose illness is driven by non–T-cell mechanisms are unlikely to receive direct benefit from this early laboratory-focused work.
Why it matters
Potential benefit: If successful, the work could identify a new drug target that helps reduce harmful T cell activity in autoimmune diseases.
How similar studies have performed: Ion channels are established drug targets in other fields, but applying channel-targeting to autoimmune diseases is relatively new and this project builds on early genetic screens pointing to ATP1B3.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Feske, Stefan — New York University School of Medicine
- Study coordinator: Feske, Stefan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.